United Kingdom-Edinburgh: Pharmaceutical products

Search Tenders

Pharmaceutical & Medical United Kingdom-Edinburgh: Pharmaceutical products

United Kingdom-Edinburgh: Pharmaceutical products

United Kingdom-Edinburgh: Pharmaceutical products has been closed on 14 Nov 2018. It no longer accepts any bids. For further information, you can contact the The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

Bellow, you can find more information about this project:

Location: United Kingdom

General information

Donor:

The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")

Industry:

Pharmaceutical & Medical

Status:

Closed

Timeline

Published:

21 Jan 2022

Deadline:

14 Nov 2018

Value:

Not available

Contacts

Phone:

+44 1698794410

+44 2088187374

+44 1312252525

Email: [email protected]

Description

Modification notice

Modification of a contract/concession during its term

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1)Name and addresses

Official name: The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
Postal address: Gyle Square (NSS Head Office), 1 South Gyle Crescent
Town: Edinburgh
NUTS code: UKM Scotland
Postal code: EH12 9EB
Country: United Kingdom
E-mail: [email protected]
Telephone: +44 1698794410
Internet address(es):
Main address: http://www.nhsscotlandprocurement.scot.nhs.uk/
Address of the buyer profile: https://www.publiccontractsscotland.gov.uk/search/Search_AuthProfile.aspx?ID=AA11883

Section II: Object

II.1)Scope of the procurement

II.1.1)Title:

Supply of Interferon Beta-1a (Rebif®)

Reference number: NP91618 (d)

II.1.2)Main CPV code

33600000 Pharmaceutical products

II.1.3)Type of contract

Supplies

II.2)Description

II.2.2)Additional CPV code(s)

33600000 Pharmaceutical products

II.2.3)Place of performance

NUTS code: UKM Scotland

Main site or place of performance:

All entities constituted pursuant to the National Health Services (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to New Public Bodies (Joint Working) Scotland Act 2014.

II.2.4)Description of the procurement at the time of conclusion of the contract:

This procurement is for the supply of Interferon Beta-1a (Rebif®) to NHSScotland.

II.2.7)Duration of the contract, framework agreement, dynamic purchasing system or concession

Start: 01/12/2018

End: 28/02/2022

II.2.13)Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

Section IV: Procedure

IV.2)Administrative information

IV.2.1)Contract award notice concerning this contract

Notice number in the OJ S: 2019/S 014-028377

Section V: Award of contract/concession

Contract No: NP91618 (d) Rebif

Title:

Supply of Interferon Beta-1a (Rebif®)

V.2)Award of contract/concession

V.2.1)Date of conclusion of the contract/concession award decision:

14/11/2018

V.2.2)Information about tenders

The contract/concession has been awarded to a group of economic operators: no

V.2.3)Name and address of the contractor/concessionaire

Official name: Merck Serono
Postal address: Stanwell road, feltham
Town: London
NUTS code: UKM Scotland
Country: United Kingdom
Telephone: +44 2088187374

The contractor/concessionaire is an SME: no

V.2.4)Information on value of the contract/lot/concession (at the time of conclusion of the contract;excluding VAT)

Total value of the procurement: 2 388 845.00 GBP

Section VI: Complementary information

VI.3)Additional information:

The total value in Section II.1.7 and V.2.4 refers to the full 39-month duration of the framework agreement.

(SC Ref:679438)

VI.4)Procedures for review

VI.4.1)Review body

Official name: Sheriff Court House
Postal address: 27 Chambers Street
Town: Edinburgh
Postal code: EH1 1LB
Country: United Kingdom
Telephone: +44 1312252525
Internet address: http://www.nhsscotlandprocurement.scot.nhs.uk/

VI.4.3)Review procedure

Precise information on deadline(s) for review procedures:

The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.

VI.5)Date of dispatch of this notice:

18/01/2022

Section VII: Modifications to the contract/concession

VII.1)Description of the procurement after the modifications

VII.1.1)Main CPV code

33600000 Pharmaceutical products

VII.1.2)Additional CPV code(s)

VII.1.3)Place of performance

NUTS code: UKM Scotland

VII.1.4)Description of the procurement:

This modification of contract term from 01/03/2022 to 31/08/2022 is to meet the additional demands of the Scottish Health and Social Care sector during the current Covid-19 pandemic and to maintain necessary supply and remove unnecessary disruption from the Authority at this time in line with Regulation 72(1)(b) of the Public Contracts (Scotland) Regulations 2015

VII.1.5)Duration of the contract, framework agreement, dynamic purchasing system or concession

Start: 01/03/2022

End: 31/08/2022

VII.1.6)Information on value of the contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: 210 374.00 GBP

VII.1.7)Name and address of the contractor/concessionaire

Official name: Merck Serono
Postal address: Stanwell road, feltham
Town: Middlesex
NUTS code: UK United Kingdom
Country: United Kingdom

The contractor/concessionaire is an SME: no

VII.2)Information about modifications

VII.2.1)Description of the modifications

Nature and extent of the modifications (with indication of possible earlier changes to the contract):

VII.2.2)Reasons for modification

Need for modification brought about by circumstances which a diligent contracting authority/entity could not foresee (Art. 43(1)(c) of Directive 2014/23/EU, Art. 72(1)(c) of Directive 2014/24/EU, Art. 89(1)(c) of Directive 2014/25/EU)

Description of the circumstances which rendered the modification necessary and explanation of the unforeseen nature of these circumstances:

VII.2.3)Increase in price

Updated total contract value before the modifications (taking into account possible earlier contract modifications and price adaptions and, in the case of Directive 2014/23/EU, average inflation in the Member State concerned)

Value excluding VAT: 1 682 988.00 GBP

Total contract value after the modifications

Value excluding VAT: 1 893 362.00 GBP

http://ted.europa.eu/udl?uri=TED:NOTICE:36898-2022:TEXT:EN:HTML&src=0&tabId=2

Featured tenders